Glatiramer acetate: evidence for a dual mechanism of action - PubMed

Affiliations

• PMID: 18317674
• DOI: 10.1007/s00415-008-1005-5

Review

Glatiramer acetate: evidence for a dual mechanism of action

François Blanchette et al. J Neurol. 2008 Mar.

Abstract

Glatiramer acetate is a disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis. Since its discovery almost four decades ago, and in particular since the observation of its beneficial clinical effects in the late 1980s and early 1990s, numerous data have been generated and contribute pieces of a puzzle to help explain the mechanism of action of glatiramer acetate. Two major themes have emerged, namely (i) the induction of glatiramer acetate-reactive TH2 immunoregulatory cells, and (ii) the stimulation of neurotrophin secretion in the central nervous system that may promote neuronal repair.

Similar articles

• Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.

  Van Kaer L. Van Kaer L. Exp Neurol. 2011 Jan;227(1):19-23. doi: 10.1016/j.expneurol.2010.10.009. Epub 2010 Oct 20. Exp Neurol. 2011. PMID: 20969865 Free PMC article.

• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].

  Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, et al. Neurology. 2001 Dec;57(12 Suppl 5):S46-53. Neurology. 2001. PMID: 11902595 No abstract available.

• [Mechanisms of glatiramer acetate action in demyelinating diseases: antigen-specific, organ-specific or process-specific treatment].

  Boĭko AN, Zhuchenko TD, Gusev EI. Boĭko AN, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;Suppl:52-8. Zh Nevrol Psikhiatr Im S S Korsakova. 2002. PMID: 12418393 Review. Russian.

• Atorvastatin and glatiramer acetate: new hope in MS?

  Bradbury J. Bradbury J. Lancet Neurol. 2006 May;5(5):386-7. doi: 10.1016/s1474-4422(06)70431-8. Lancet Neurol. 2006. PMID: 16639832 No abstract available.

• Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

  Simpson D, Noble S, Perry C. Simpson D, et al. CNS Drugs. 2002;16(12):825-50. doi: 10.2165/00023210-200216120-00004. CNS Drugs. 2002. PMID: 12421116 Review.

Cited by

• Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?

  Inyang KE, Folger JK, Laumet G. Inyang KE, et al. J Neuroimmune Pharmacol. 2021 Sep;16(3):531-547. doi: 10.1007/s11481-021-10000-z. Epub 2021 May 26. J Neuroimmune Pharmacol. 2021. PMID: 34041656 Review.

• Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.

  Van Kaer L. Van Kaer L. Exp Neurol. 2011 Jan;227(1):19-23. doi: 10.1016/j.expneurol.2010.10.009. Epub 2010 Oct 20. Exp Neurol. 2011. PMID: 20969865 Free PMC article.

• Glatiramer acetate treatment increases stability of spinal synapses and down regulates MHC I during the course of EAE.

  Scorisa JM, Freria CM, Victorio SC, Barbizan R, Zanon RG, Oliveira AL. Scorisa JM, et al. Int J Biol Sci. 2011;7(8):1188-202. doi: 10.7150/ijbs.7.1188. Epub 2011 Oct 27. Int J Biol Sci. 2011. PMID: 22043176 Free PMC article.

• Glatiramer acetate attenuates the activation of CD4⁺ T cells by modulating STAT1 and -3 signaling in glia.

  Ahn YH, Jeon SB, Chang CY, Goh EA, Kim SS, Kim HJ, Song J, Park EJ. Ahn YH, et al. Sci Rep. 2017 Jan 17;7:40484. doi: 10.1038/srep40484. Sci Rep. 2017. PMID: 28094337 Free PMC article.

• Impact of pregabalin treatment on synaptic plasticity and glial reactivity during the course of experimental autoimmune encephalomyelitis.

  Silva GA, Pradella F, Moraes A, Farias A, dos Santos LM, de Oliveira AL. Silva GA, et al. Brain Behav. 2014;4(6):925-35. doi: 10.1002/brb3.276. Epub 2014 Sep 2. Brain Behav. 2014. PMID: 25365796 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information